Macquarie Group’s Allogene Therapeutics ALLO Stock Holding History

Macquarie Group’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-146,779	Closed	-$182K	–	874
2025 Q3	$182K	Hold	146,779	–	–	﹤0.01%	1495
2025 Q2	$166K	Hold	146,779	–	–	﹤0.01%	1549
2025 Q1	$214K	Hold	146,779	–	–	﹤0.01%	1531
2024 Q4	$313K	Hold	146,779	–	–	﹤0.01%	1479
2024 Q3	$411K	Hold	146,779	–	–	﹤0.01%	1497
2024 Q2	$342K	Hold	146,779	–	–	﹤0.01%	1513
2024 Q1	$656K	Hold	146,779	–	–	﹤0.01%	1422
2023 Q4	$471K	Hold	146,779	–	–	﹤0.01%	1479
2023 Q3	$465K	Hold	146,779	–	–	﹤0.01%	1448
2023 Q2	$729K	Hold	146,779	–	–	﹤0.01%	1406
2023 Q1	$725K	Hold	146,779	–	–	﹤0.01%	1418
2022 Q4	$923K	Sell	146,779 -593	-0.4%	-$5.49K	﹤0.01%	1436
2022 Q3	$1.6M	Sell	147,372 -1,097	-0.7%	-$14.9K	﹤0.01%	1299
2022 Q2	$1.69M	Hold	148,469	–	–	﹤0.01%	1352
2022 Q1	$1.35M	Hold	148,469	–	–	﹤0.01%	1472
2021 Q4	$2.21M	Buy	148,469 +140	+0.1%	+$2.47K	﹤0.01%	1347
2021 Q3	$3.81M	Hold	148,329	–	–	﹤0.01%	1182
2021 Q2	$3.87M	Hold	148,329	–	–	﹤0.01%	1209
2021 Q1	$5.24M	Sell	148,329 -454	-0.3%	-$15.3K	0.01%	897
2020 Q4	$3.76M	Hold	148,783	–	–	0.01%	933
2020 Q3	$5.61M	Hold	148,783	–	–	0.01%	798
2020 Q2	$6.37M	Buy	148,783 +2,004	+1%	+$72.5K	0.01%	741
2020 Q1	$2.85M	Hold	146,779	–	–	0.01%	841
2019 Q4	$3.81M	Hold	146,779	–	–	0.01%	873
2019 Q3	$4M	Hold	146,779	–	–	0.01%	820
2019 Q2	$3.94M	Hold	146,779	–	–	0.01%	837
2019 Q1	$4.24M	Hold	146,779	–	–	0.01%	819
2018 Q4	$3.95M	Buy	+146,779	New	+$3.9M	0.01%	809

Other funds holding ALLO

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Macquarie Group's ALLO Position: Q4 2025 in Review

Macquarie Group sold out of Allogene Therapeutics (ALLO) in Q4 2025, closing a stake of 146,779 shares — an estimated $182K sold.

Macquarie Group first reported a position in ALLO in Q4 2018 and held it in 28 quarters. The position peaked at $6.37M in Q2 2020. 172 funds tracked by Wall St. Rank hold ALLO as of Q4 2025.

Macquarie Group reported no remaining Allogene Therapeutics position as of Q4 2025 after selling out during the quarter.
Macquarie Group sold 146,779 Allogene Therapeutics shares in Q4 2025, an estimated $182K.
Macquarie Group first reported a position in Allogene Therapeutics in Q4 2018 and held it in 28 quarters.
Macquarie Group's Allogene Therapeutics position peaked at $6.37M in Q2 2020.
172 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.